The principal investigators’ research will focus on defining specific factors and cells that may be targeted to treat IBD. They will test whether nanoparticle-mediated manipulation of pro- and anti-inflammatory factors can limit intestinal inflammation and promote wound healing during IBD. To accomplish this, they will use advanced approaches employing siRNA nanoparticles that target key pro-healing and anti-inflammation factors, which are involved in the pathogenesis of IBD.
Complementary models of acute and chronic intestinal inflammation will also be used to further define which specific intestinal cells should be targeted by nanoparticles and the beneficial effect of this delivery system in dampening inflammation and promoting wound healing. These studies will help to define novel biological functions of nanoparticle-mediated drug delivery during intestinal inflammation and have the potential to optimize treatment of human IBD.
An abstract of the grant, 1R01DK107739-01A1, is available at the NIH’s Project RePORTer website.